Alvogen Settles Global Eylea Biosimilar Patent Disputes

Alvogen has reached a licensing and settlement agreement with Regeneron Pharmaceuticals and Bayer, resolving all remaining worldwide patent disputes related to Alvogen's biosimilar to Eylea (aflibercept). This agreement grants Alvogen global rights to manufacture and supply its aflibercept biosimilar, building on a previous agreement for the U.S. market. The settlement allows Alvogen and its commercial partners, including Advanz Pharma, Stada Arzneimittel, Biogaran, and Fuji Pharma, to market and sell the biosimilar in the United Kingdom and Canada from January 1, 2026, in the European Economic Area and other countries from May 1, 2026, and in Japan with full indications from November 1, 2026. The biosimilar has already received marketing approvals from the European Union===European Commission, the Medicines & Healthcare products Regulatory Agency, and the Japanese Japan===Ministry of Health, Labour and Welfare.